Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for NextCure, Inc. (NXTC : NSDQ)

• Company Description    NextCure Inc. is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company's product candidate consists of NC318 and NC410 which are in clinical stage. NextCure Inc. is based in Beltsville, Maryland. Number of Employees: 99

• Price / Volume Information    Yesterday's Closing Price: $1.68 Daily Weekly Monthly 20 Day Moving Average: 63,066 shares Shares Outstanding: 27.83 (millions) Market Capitalization: $46.67 (millions) Beta: 0.06 52 Week High: $5.27 52 Week Low: $1.16 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 5.44% 1.45% 12 Week 14.05% 5.87% Year To Date 18.90% 8.15%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9000 VIRGINIA MANOR ROAD SUITE 200 - BELTSVILLE,MD 20705 USA ph: 240-399-4900 fax: - ir@nextcure.com http://www.nextcure.com

• General Corporate Information    Officers Michael Richman - President; Chief Executive Officer and Director David Kabakoff - Chairman Steven P. Cobourn - Chief Financial Officer Anne Borgman - Director Ellen G. Feigal - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 65343E108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/23 Next Expected EPS Date: 08/03/23 Share - Related Items Shares Outstanding: 27.83 Most Recent Split Date: (:1) Beta: 0.06 Market Capitalization: $46.67 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.60 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.40 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/03/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.30 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 21.62% vs. Previous Quarter: 6.45% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/23 - -40.05 12/31/22 - -39.27 09/30/22 - -35.97 ROA 03/31/23 - -37.54 12/31/22 - -37.22 09/30/22 - -34.53 Current Ratio 03/31/23 - 23.77 12/31/22 - 17.97 09/30/22 - 29.76 Quick Ratio 03/31/23 - 23.77 12/31/22 - 17.97 09/30/22 - 29.76 Operating Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Net Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Pre-Tax Margin 03/31/23 - - 12/31/22 - - 09/30/22 - - Book Value 03/31/23 - 5.54 12/31/22 - 6.03 09/30/22 - 6.54 Inventory Turnover 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Equity 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00 Debt-to-Capital 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00

Powered by Zacks Investment Research ©